University of California, San Francisco **Prepared: 1/28/2011**

CIRRICULUM VITAE

Name: **Kathleen M. Giacomini**

Position: Co-Chair
Department of Bioengineering and Therapeutic Sciences
Schools of Pharmacy and Medicine

Professor
Departments of Bioengineering and Therapeutic Sciences, Pharmaceutical Chemistry, and Cellular and Molecular Pharmacology
Schools of Pharmacy and Medicine

Address: Room RH584, Box 2911
Mission Bay Campus 1550 4th St Bldg 19B
University of California, San Francisco
San Francisco, CA 94143

Voice: (415) 476-1936
FAX: (415) 514-4361
email: kathy.giacomini@ucsf.edu
www: http://bts.ucsf.edu.giacomini/

EDUCATION:

1974	University of Texas, Houston, TX	B.S.	Pharmacy
1979	State University of New York at Buffalo, Buffalo, NY	Ph.D.	Pharmaceutics
1979-1981	Stanford University School of Medicine, Division of Clinical Pharmacology Stanford, CA	Postdoc	Pharmacology

PRINCIPAL POSITIONS HELD:

1982-87	University of California, San Francisco	Assistant Professor	Pharmacy Pharm. Chem. Pharmacology
1987-91	University of California, San Francisco	Associate Professor	Pharmacy Pharm. Chem. Pharmacology
1991-now	University of California, San Francisco	Professor	BTS Pharm. Chem. Cell. and Molecular Pharmacology

OTHER POSITIONS HELD CONCURRENTLY:

1990-95	UCSF Department of Pharmacy	Vice Chair, Director of Graduate Program

1997-98	UCSF Department of Biopharmaceutical Sciences	Vice Chair
1998-2009	UCSF Department of Biopharmaceutical Sciences	Chair
2006-now	Biomedical Sciences (BMS) Graduate Program	Faculty Member
2009-now	UCSF Department of Bioengineering and Therapeutic Sciences	Co-Chair

HONORS AND AWARDS:

1983-84	Long Foundation Award for Excellence in Teaching, School of Pharmacy, University of California, San Francisco
1984-85	(b) (4)
1985-86	Distinguished Teaching Award, University of California, San Francisco, Academic Senate
1990	Leon Goldberg Young Investigator Award, American Society of Clinical Pharmacology and Therapeutics
1992	Recipient, Fogarty International Fellowship National Institutes of Health
1994	(b) (4)
1997	(b) (4)
1999	(b) (4)
1999	International Pharmaceutical Federation (FIP) Scientist of the Year
2000	Guttman Lecturer, University of Kentucky
2002-03	(b) (4) Distinguished Bill Abram's Lectureship (FDA) Distinguished Gerhard Levy Lectureship (SUNY Buffalo)
2005	Paul Daws on Biotechnology Award, American Association of College of Pharmacy
2006	Distinguished Scientist Award in Drug Metabolism, American Association of Pharmaceutical Scientist
2007	Pharmaceutical Sciences World Congress (PSWC) Research Achievement Award
2007	International Woman Scientist Award, Academy of Pharmaceutical Sciences and Technology, Japan
2008	Japan Society for the Promotion of Science (JSPS) Invitation Fellowship Program for Research in Japan

2009	Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology and Therapeutics (ASCPT)
2009	UCSF Postdoctoral Scholars Association Outstanding Mentor Award
2010	American College of Clinical Pharmacy Therapeutic Frontiers Lecture Award
2011	Scheele Award, Swedish Academy of Pharmaceutical Sciences

KEYWORDS/AREAS OF INTEREST:

Pharmaceutical Sciences, Pharmacogenomics, Transporter Biology.

PROFESSIONAL ACTIVITIES

PROFESSIONAL ORGANIZATIONS

Memberships

American Association of Pharmaceutical Scientists	Elected Fellow (1993)
American Society for Clinical Pharmacology and Therapeutics	Vice President (1996)
American Association for the Advancement of Science	Elected Fellow (2001)
Institute of Medicine	Elected Member (2006)
NIH/NAGMS Advisory Council	Member
World Health Organization	Member
American Society of Pharmacology and Experimental Therapeutics	
International Society for the Study of Xenobiotics	

SERVICE TO PROFESSONAL PUBLICATIONS:

1986-now	Editorial Board, Clinical Pharmacology and Therapeutics
2001-now	Editorial Board, Pharmacogenetics
2005-06	Vice Chair, Scientific Award Committee, American Society for Clinical Pharmacology and Therapeutics
2005-06	Council of Clinical Pharmacology, American Society for Clinical Pharmacology and Therapeutics

INVITED PRESENTATIONS

REGIONAL AND OTHER INVITED PRESENTATIONS

Invited Lectures and Seminars

1995 Symposium Organizer and Speaker: "Nucleosides, Oligonucleotides and Genes: Intracellular Targeting and Disposition." American Association of Pharmaceutical Scientists, Annual Meeting.

1996 Invited Speaker: "Nucleoside Transporters: Molecular Studies." University of Southern California, Health Sciences Seminar Series.

Invited Speaker: "Membrane Transporters in Drug Absorption, Disposition and Targeting." Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, 1996.

Invited Speaker: "Double, Double, Toil and Trouble: Isoforms of Organic Cation Transporters." Annual Retreat for the Department of Pharmaceutical Chemistry at the Asilomar Conference Center, Monterey, CA.

1997 Invited Speaker: "Balancing a Family and a Career in Science." University of California, San Francisco, Women in Life Sciences.

Invited Speaker: "Membrane Transporters in Drug Disposition." University of California, San Francisco, Symposium: The Impact of Pharmacokinetics in Modern Drug Development.

Invited Speaker: "Organic Cation Transporters." Gordon Research Conference on Drug Metabolism, Holderness, New Hampshire, "The Impact of Pharmacokinetics in Modern Drug Development."

Invited Speaker: "Organic Cation Transporters in Drug Disposition." American Association of Pharmaceutical Scientists, Symposium on Drug Transporters, National Meeting, Boston, MA.

Invited Speaker: "Nucleoside Transporters in Drug Absorption and Disposition." Pfizer, Inc., 30th Anniversary of Drug Metabolism, New Jersey, NJ.

1998 Invited Speaker: "Novel Organic Cation Transporters." International Meeting of the International Society for Study of Xenobiotics, Cairns, Australia.

1999 Invited Speaker: "Nucleoside transporters: Substrate recognition groups and intracellular trafficking," NIH-AAPS Frontier Symposium, Bethesda, MD.

Invited Speaker: "Concentrative Nucleoside Transporters in Drug Disposition and Targeting." American Society for Clinical Pharmacology and Therapeutics, San Antonio, TX.

Invited Speaker: "Pharmacogenomics of Membrane Transporters." American Association of Pharmaceutical Scientists, New Orleans, LA.

Invited Speaker: "The structural basis and significance of variations in nucleoside transporter genes." Symposium on Pharmacogenetics, Ann Arbor, MI.

Invited Speaker: "Concentrative Nucleoside Transporters in Drug Disposition and Response." Federation Internationale Pharmaceutique (FIP) World Congress of Pharmacy and Pharmaceutical Sciences '99, Barcelona, Spain.

2000 Invited Speaker: "A Polymorphism in the Gene Encoding the Human Liver Organic Cation Transporter, hOCT1, Produces Functional Changes." American Society for Clinical Pharmacology and Therapeutics with the Canadian Society for Clinical Pharmacology, Los Angeles, CA. (Wednesday, Mar. 15, 2000

Invited Speaker: "Tailoring Drugs to Fit Your Genes." University of California, San Francisco, Public Service Program, San Francisco, CA.

Invited Plenary Speaker: "Understanding the Role of Membrane Transporters in Human Drug Response." The Academy of Pharmaceutical Science and Technology (Japan) with the Association de Pharmacie Galénique Industrielle, San Francisco, CA.

Invited Speaker: "Pharmacogenetics Studies of Membrane Transporters." 10th North American ISSX Meeting Mechanisms, Models, and Methods for the Next Century, Indianapolis, Indiana.

Honorary Lecturer: " Structural domains responsible for substrate discrimination in nucleoside and organic cation transporters." The Guttman Lectureship University of Kentucky, School of Pharmacy.

2001 Invited Speaker: Membrane Transporters: From identification to drug discovery. "Overview of Nucleoside Transporters" Interlaken, Switzerland.

Invited Speaker: "Pharmacogenetics of Membrane Transporter." American Society for Clinical Pharmacology and Therapeutics, Orlando, Florida.

Honorary Lecturer: Polymorphisms in Membrane Transporters: Role in Drug Response. The Wagner Lectureship School of Pharmacy, University of Michigan.

Invited Keynote Speaker: "Natural Variation in Membrane Transporter." Gordon Research Conference on Drug Metabolism. Holderness, Connecticut.

Invited Speaker: "Fundamentals of Membrane Transporters with Special Emphasis on in Vivo Role Polymorphism and Coordinate Regulation of P-glycoprotein." AAPS Annual Meeting and Exposition, Denver, CO.

2002 Invited Speaker: "Pharmacogenetics of Drug Transporters." American Society for Pharmacology & Experimental Therapeutics. New Orleans.

Honorary Lecturer: "Pharmacogenetics of Membrane Transporters: Linking Clinical and Basic Research." Bill Abram's Lectureship, FDA, Washington, DC.

Honorary Lecturer: "Pharmaceutical Sciences in the New Millennium: Human Genetics Converges with Pharmacokinetics and Pharmacodynamics." Gerhard Levy Lectureship, Buffalo, NY.

Invited Speaker: "The Impact of the Human Genome Project on Drug Development and Use: Tailoring Drugs to Individuals." State Legislature Presentation, Sacramento, CA.

2003 Invited Speaker: "Natural Variation in Human Membrane Transporter." Annual Meeting, Pharmacogenetic Research Network, Memphis, TN.

Invited Speaker: "Genetic Variation in Membrane Transporters: Implications to Drug Response." American Society for Clinical Pharmacology and Therapeutics, Washington, DC.

Invited Speaker: Perspectives in Transport Biology. FASEB Summer Research Conference, Tucson, AZ.

Invited Speaker: Cancer and Leukemia Group B: Pharmacogenomics of Transporters in Cancer Drug Therapy, Phoenix, AZ.

2004 Invited Speaker: Frontier in Biology. Stanford University, Stanford, CA.

Invited Speaker: "Xenobiotic Transporters inn Drug Development." Genentech Development Seminar Series, CA.

Invited Plenary Speaker: Keystone Symposia Biological Discovery Using Diverse High-Throughput Data, Steamboat Springs, CO.

Invited Plenary Speaker: Pharmaceutical Sciences World Congress, Kyoto, JAPAN.

Invited Speaker: "Genetic Variation in Influx Transporters and Anti-Cancer Drug Resistance." 7th International Meeting of ISSX, Vancouver, CANADA.

Invited Speaker: “Pharmacogenetics Membrane Transporters.” School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO.

Invited Speaker: Drug Metabolism Seminar Series. “Pharmacogenetics of Membrane Transporter Implications to Drug Response.” Merck, Philadelphia, PA.

Distinguished Lectureship: “Pharmacogenomics of Membrane Transporters: Implications to Drug Response.” University of Pittsburgh School of Pharmacy.

2005 Organizer: “Pharmacogenomics in Action.” AAAS Meeting, Washington, DC.

Co-Chairs: “Pharmacogenomics: Bench to Bedside,” American Society for Clinical Pharmacology & Therapeutics.

Award Recipient: “Dialogue on Excellence Award Ceremony,” AACP, Cincinnati, OH.

Invited Speaker: “Genetic Variation in Drug Transporters in Ethnically Diverse Human Populations.” 4th Annual Multidisciplinary Scientific Symposium (Moving Targets), University of Southern California, CA.

Invited Speaker: “Genetic Variation of Membrane Transporters.” FASEB Summer Research Conference; Perspective in Transport Biology. Vermont Academy, Saxtons River, VT.

Featured Speaker: “Biomedical Transporters,” St. Gallen, Switzerland.

Invited Speaker: “Personalized Medicines: Can We Tailor Drugs to Individuals Based on Their Genes?” Fall 2005 Colloquim Series in Microbiology, Cell & Molecular Biology, San Francisco State University, CA.

2006 Invited Speaker: “Genome/Stem Cell Basis 101 for Practicing Pharmacists,” Pharmacy Association Annual Meeting, San Francisco, CA.

Invited Speaker: “New Drugs Made for you… Tailored to Your Genetic Makeup, Osher Lifelong Learning Institute, UCSF.

Invited Speaker: “Pharmacogenomics in Drug Targeting,” Biomedical Sciences Retreat, UCSF.

Keynote Speaker: “Strategies in Personalized Medicine: The role of pharmaceutics in predictive drug therapy,” Globalization of Pharmaceutics Education Network (GPEN), Inc., Lawrence, Kansas.

Invited Speaker: “Organic Cation Transporters in Targeting Anti-Cancer Platinum Drugs,” Experimental Therapeutics in PDAC, Mount Zion Campus, UCSF.

Keynote Speaker: “Pharmacogenomics and its Current Status,” Sunrise Session at the American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX.

2007 Organizer and Moderator: “Genetic Targeting of Drug Therapies,” AAAS Annual Meeting, San Francisco, CA.

Participant: “Building a National Research Model: The Future of HMO-Based Research,” 13th Annual HMO Research Network Conference, Portland, OR.

Keynote Speaker: “Transporter Polymorphisms Associated with Response to Metformin,” 108th Annual American Society for Clinical Pharmacology and Therapeutics (ASCPT), Anaheim, CA.

Keynote Speaker: “Functional genomics of membrane transporters,” Pharmaceutical Sciences World Congress (PSWC), Amsterdam.

Invited Speaker: ”Pharmacogenetics of Membrane Transporters: From SNP Discovery to Clinical Drug Response,” Ellis Grollman’s Lecture in Pharmaceutical Sciences, Baltimore, MD.

Invited Speaker: “Personalized Medicines: New Drugs Made for You,” Stanford Genomic Course, Stanford University.

2008 Moderator: “Genetic Polymorphism of Transporters: Effect on Pharmacodynamics,” Pharmacogenetics Research Network (PGRN)-Riken-JSSX Joint Workshop on Pharmacogenomics in Drug Development, University of Tokyo, JAPAN.

Speaker: “Transporter Genomics and Drug Response,” 1st Canadian Human Genetics Conference, Ottawa, CANADA.

Invited Speaker: “Pharmacogenomics: Personalizing Therapy,” Coalition for the Life Sciences, Bethesda, MD.

Invited Speaker: “Genetic Determinants of Renal Drug Clearance and Toxicity” and “Molecular Determinants of Specificity in the SLC22A Family,” 15th North American Regional Meeting of the ISSX, San Diego, CA.

2009 Invited Speaker: “Genetic variation in solute carrier genes: Ethnic diversity and biopharmaceutical relevance,” American Society for Clinial Pharmacology and Therapeutics. National Harbor, Maryland

Invited Speaker: “Organic Cation Transporters in Pharmacology and Toxicology,” American College of Toxicology 30th Annual Meeting, Palm Springs, CA.

Invited Speaker: “Possible Criteria that Warrant In Vivo Renal Transporters Mediated DDI Studies and In Vitro Assessments,” American Association of Pharmaceutical Scientists Annual Meeting, Los Angeles, CA.

2010 Invited Speaker: “Pharmacogenetics of Metformin,” 3rd Annual Future of Genomic Medicine Conference, La Jolla, CA.

Invited Speaker: “Personalizing Anti-diabetic Drug Therapy,” Grant R. Wilkinson Lectureship, Vanderbilt University, Nashville, TN.

Invited Speaker: “Transporters in Drug-Induced Ototoxicity and Nephrotoxicity,” American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, GA.

Invited Speaker: “The SOPHIE Study Experience and Analysis of Transporter Expression to Enable Personalized Medicine,” International Society for the Study of Xenobiotics Annual Meeting, Indianapolis, IN.

Invited Speaker: “American College of Clinical Pharmacy Therapeutic Frontiers Lecture” American College of Clinical Pharmacy Annual Meeting, Austin, TX.

GOVERNMENT and OTHER PROFESSIONAL SERVICE:

1989	National Institute of General Medical Sciences	*Ad Hoc* Member to Pharmacological Science, Study Section
1990	National Institute of General Medical Sciences	Ad Hoc Member of a Site Visit Team for Evaluation of Graduate Programs
1990-94	National Institute of General Medical Sciences	Pharmacological Sciences Study Section
1990-94	Food and Drug Administration	Advisory Panel on Generic Drugs
1995	American Association of Pharmaceutical Scientists (AAPS)	Symposium Chair, Section on Pharmacokinetics/ Pharmacodynamics and Drug Metabolism, Nucleosides, Oligonucleotides and Genes: Transport and Intracellular Targeting
1995-now	American Society for Clinical Pharmacology and Therapeutics	Government Affairs Committee
1996-97	American Association of Pharmaceutical Scientists (AAPS)	Chair, Fellow Selection Committee
1997-99	American Society for Clinical Pharmacology and Therapeutics	Executive Committee
1998	American Society for Clinical Pharmacology and Therapeutics	Vice President
1999-2000	American Association of Pharmaceutical Scientists (AAPS)	Vice Chair, Focus Group Membrane Transporters
2000	National Institute of General Medical Sciences	Special Study Section Reviewer
2000-06	American Society for Clinical Pharmacology and Therapeutics	Council for Clinical Pharmacology
2000-now	PGRN (NIH Pharmacogenetics Research Network)	Steering Committee Member
2001-02	American Association of Pharmaceutical Scientists (AAPS)	Chair, Focus Group Membrane Transporters
2003-06	American Society for Clinical Pharmacology and Therapeutics	Vice Chair, Scientific Awards Committee
2003-now	PGRN (NIH Pharmacogenetics Research Network)	Coordinating Committee Member
2003-now	PGRN (NIH Pharmacogenetics Research	Steering Committee Vice Chair

	Network)	
2005-06	PGRN (NIH Pharmacogenetics Research Network)	Steering Committee Chair
2005-08	National Advisory of General Medical Sciences Council	Member
2009-13	Food and Drug Administration	Advisory Panel on Clinical Pharmacology
2008-now	St. Jude's Hospital	Scientific Advisory Board
2008-now	UCSF Cancer Center	Scientific Advisory Board

UNIVERSITY AND PUBLIC SERVICE

UNIVERSITY SERVICE

UCSF CAMPUS-WIDE

1995	(b) (4)
1996-97	
1997-98	
1997	
1998	In-Residence Policy Committee (Chair)
1998	Committee on Parnassus Heights Release Space
2000	Executive Committee, Program in Human Genetics
2004	(b) (4)
2004	Chair, JETS (Joint Enterprise in Therapeutic Sciences), (Chair)
2004	Member, UCSF Comprehensive Cancer Center (Member)
2004	CVRI Planning Committee
2005	Search Committee for Chair of Epidemiology and Biostatistics (Member)
2005	Search Committee for Chair, Department of Lab Medicine (Member)
2005	Bay Area Biotech-FDA-UCSF/Academic: Personalized Medicines (Moderator)
2005	Bay Area Biotech-FDA-UCSF/Academic: Modeling and Simulation (Participant)
2006	Member, Liver Center's Executive Committee (Member)
2006	Search Committee for Chair, Department of Medicine (Member)
2006	Search Committee for Chair, Department of Laboratory Medicine (Member)
2006	Search Committee for Cardiac Stem Cell and Development Biology, GICD (Member)
2006	Search Committee for DNA Bank Director (Member)
2006	Search Committee for Psychiatric Drug Discovery, Dept. of Psychiatry (Member)
2006	Search Committee for Faculty, Holly Smith Distinguished Professorship in Science and Medicine (Member)
2010	Long Range Development Plan Oversight Committee

SCHOOL OF PHARMACY

1996-98	Executive Committee, School of Pharmacy (Elected Member)
1998-now	Leadership Group, School of Pharmacy (Member)

DEPARTMENTAL SERVICE

1990-now	Department of Biopharmaceutical Sciences	Program Director, Graduate Program in Pharmaceutics
1991	Department of Biopharmaceutical Sciences	Search Committee for Tenure Track Faculty Member
1991-95	Department of Biopharmaceutical Sciences	Program Director of the Graduate Program in Pharmaceutics
1991-95	Department of Biopharmaceutical Sciences	Vice Chair
1997	Department of Biopharmaceutical Sciences	Committee on Graduate Education (ad hoc)
1997	Department of Biopharmaceutical Sciences	Vice Chair
1998-2009	Department of Biopharmaceutical Sciences	Chair
2009-now	Department of Bioengineering and Therapeutic Sciences	Co-Chair

TEACHING and MENTORING

FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS:

Academic Year	Course Number Quarter	Course Title	Nature of Contribution	Hrs/Qtr Instruction	Total Enroll
2004-05	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	20	8
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer/Director	12	13
2005	Sp	BPS 115 Genetics and Pharmacogenetics	Lecturer/Director	4	124
2005-06	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	17	22
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer/Director	12	17
2006-07	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	18	20
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer/Director	14	17
2007-08	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	12	20
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer/Director	8	23
2008-09	F	PSPG 245A	Lecturer/Director	20	20

		Kinet. Drug Abs. Disp.			
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer	6	26
2009-10	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	20	9
	Sp	PSPG 245C Principles of Pharmacogenomics	Lecturer	4	9
2010-11	F	PSPG 245A Kinet. Drug Abs. Disp.	Lecturer/Director	20	18

Doctoral Dissertations Completed under Mentorship

1983-89 (b) (6), Ph.D., Pharmaceutical Chemistry. Dr. (b) (6) is retired.

1984-87 (b) (6), Ph.D., Pharmaceutical Chemistry. Dr. (b) (6) is retired.

1984-88 (b) (6) Ph.D., Pharmaceutical Chemistry. Dr. (b) (6) is currently a research scientist at .

1985-91 (b) (6) Ph.D., Pharmaceutical Chemistry.

1989-92 (b) (6), Ph.D. Research Scientist, (b) (6) (b) (6).

1990-94 (b) (6) Ph.D., Research Scientist, (b) (6) (b) (6)

1991-96 (b) (6), Ph.D., Senior Scientist, (b) (6) (b) (6)

1991-96 (b) (6), Ph.D., Research Scientist, (b) (6).

1992-97 (b) (6), Ph.D.,

1992-98 (b) (6) Ph.D., Research Scientist, (b) (6)

1995-98 (b) (6) Ph.D., Scientist, (b) (6).

1995-98 (b) (6) Ph.D., Associate Professor, (b) (6)

1996-00 (b) (6) Ph.D., Senior Scientist and (b) (6)).

1996-01 (b) (6) Research Scientist (b) (6)

1998-02 (b) (6) Associate Scientist, (b) (6) Assistant Member,

2000-03 (b) (6) M.S., Clinical Pharmacist

2001-05 (b) (6) Ph.D., (b) (6)

2002-07 (b) (6) Ph.D., Research Associate at (b) (6)

2003-07 (b) (6) Ph.D., Research Scientist at (b) (6), Ph.D., Assistant Professor;

2004-08 (b) (6) Ph.D., Scientist, (b) (6), Ph.D, Analyst Clinical Development, (b) (6)

2004-09 (b) (6) Ph.D., Fellow, (b) (6)

2004-09 (b) (6) Ph.D., Pursing (b) (6)

2004-2010 (b) (6) Pharmaceutical Sciences & Pharmacogenomics

Present Graduate Students under Mentorship

2004- (b) (6), Pharmaceutical Sciences & Pharmacogenomics

2008- (b) (6), Biological and Medical Informatics

2009- (b) (6) Pharmaceutical Sciences & Pharmacogenomics
Pharmaceutical Sciences & Pharmacogenomics
Pharmaceutical Sciences & Pharmacogenomics

2010- (b) (6) Pharmaceutical Sciences & Pharmacogenomics

Professional Research Personnel, Postgraduate Personnel, and Postdoctoral Fellows under Mentorship

1982-86 (b) (6) B.S. (Staff Research Associate): Renal transport studies

1983-84 (b) (6) Ph.D. (Postdoctoral Fellow): (b) (6)

1987-94 (b) (6) B.S. (Staff Research Associate): Renal transport studies

1987-89 (b) (6), B.S. (Staff Research Associate): Renal transport studies

1988-90 (b) (6) Pharm.D., Postdoctoral Fellow
, Clinical Pharmacology, Postdoctoral Fellow

1990-91 (b) (6), M.D. Professor, Anesthesia, (b) (6) (on (b) (6))

1991-93 (b) (6), (b) (6) Postdoctoral Fellow

1991-92 (b) (6) M.D., Postdoctoral Fellow

1992-94 (b) (6) Ph.D., Postdoctoral Fellow

1994-96 (b) (6) Ph.D., Postdoctoral Fellow

1994-97 [redacted] (b) (6) M.D., Postdoctoral Fellow

1996-97 Dr. [redacted] (b) (6), Visiting Scholar from [redacted] (b) (6)., JAPAN

1996-97 Dr. [redacted] (b) (6) Visiting Scientist from Taiwan, JAPAN

1996-97 [redacted] (b) (6), Visiting Student from Norway

1995-97 [redacted] (b) (6), M.S. Student from University of San Francisco

1998 [redacted] (b) (6), Visiting Student from Norway

1999 [redacted] (b) (6) Summer Internship Program
Summer Internship Program

1999-01 [redacted] (b) (6) Ph.D., Postdoctoral Scholar

1999-02 [redacted] (b) (6), Ph.D., Postdoctoral Scholar

1999 [redacted] (b) (6) Visiting Student from Norway
Visiting Student from Norway

2000-01 [redacted] (b) (6) M.D., Postdoctoral Fellow

2000-02 [redacted] (b) (6) Staff Research Associate

2002-03 [redacted] (b) (6), M.D., Ph.D., Visiting Postdoctoral Fellow

2002 [redacted] (b) (6) Staff Research Associate

2003-05 [redacted] (b) (6), Postdoctoral Fellow

2003-06 [redacted] (b) (6) Pharm.D., Postdoctoral Fellow

2004-06 [redacted] (b) (6) Ph.D., Postdoctoral Fellow

2005-06 [redacted] (b) (6) Ph.D., Visiting Postdoctoral Fellow

2005-06 [redacted] (b) (6), M.D., Ph.D., Visiting Assistant Professor

2005-09 [redacted] (b) (6), Ph.D., Postdoctoral Fellow

2006-08 [redacted] (b) (6), Ph.D., Postdoctoral Fellow

2006-09 [redacted] (b) (6) Ph.D., Postdoctoral Fellow

2007-08 [redacted] (b) (6) Ph.D., Visiting Postdoctoral Fellow

2008-09 [redacted] (b) (6), M.D., Clinical Fellow

2008-08 [redacted] (b) (6), Summer Internship (from Netherlands)
, Summer Internship (from Sidney Australia)
Pharm.D., Ph.D, Visiting Associate Professor

2008-10 [redacted] (b) (6), Staff Research Associate

2009-10 (b) (6) Postdoctoral Fellow
, Ph.D., Postdoctoral Fellow

2010-2011 (b) (6) Ph.D., Postdoctoral Fellow

2004- (b) (6) Postdoctoral Fellow
, Ph.D., Postdoctoral Fellow

2006- (b) (6), Ph.D., Postdoctoral Fellow

2009- (b) (6) Ph.D., Postdoctoral Fellow
, Ph.D., Postdoctoral Fellow
Visiting Scholar (from VietNam)
Staff Research Associate

2010- (b) (6) Ph.D., Postdoctoral Fellow

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS AND GRANTS

CURRENT

(b) (4) Postdoctoral support agreement	12/10/2010-12/15/2011 $ (b) (4)
(b) (4)	10/26/2010-4/30/2012 $ (b) (4)
1U19GM61390-11 Parent Grant NIH/NIGMS Pharmacogenetics of Membrane Transporters	07/01/2010-06/30/2015 $1,500,000 $215,000 to PI
R01 GM036780 NIH/NIGMS Cellular Mechanisms of Drug Elimination	08/01/07-05/31/2011 $219,000
(b) (4)	5/01/09-4/20/11 $ (b) (4)
(b) (4)	07/01/08-06/30/11 $ (b) (4)
U54 GM074929-01 NIH/NIGMS Specialized Center for the Protein Structure	07/04/10-06/30/15 $46,324

PENDING

(b) (4)	2.4 calendar
	0.96 calendar

PAST

1. 1-RO1 GM 42230 (PI) 1991-94, 1995-99, 1999-2003
NIH
Cellular Mechanisms of Drug Transport in the Choroid Plexus $600,000 TCD

2. (b) (4) (PI) 2002
(b) (4) TCD

3. (b) (4) (Co-Investigator) 2002-07
(b) (4) TCD

4 [redacted] (b) (4) (PI) 2003-05
[redacted] (b) (4) TCD

5. [redacted] (b) (4) 2005-08
[redacted] (b) (4) ACD

6. RO1 GM73020 2005-09
NIH
Pharmacogenomics of Human P450 Onidoreductbase $60,000 TCD

7. [redacted] (b) (4) 2006-08
[redacted] (b) (4) TCD

8. [redacted] (b) (4) (PI) 2007-09
$ [redacted] (b) (4) TCD

PEER REVIEWED PUBLICATIONS:

(1) K.M. Giacomini, T.P. Gibson, and G. Levy. Plasma Protein Binding of *d*-Propoxyphene in Normal Subjects and Anephric Patients. *J. Clin. Pharmacol*. **18**:106-109 (1977).

(2) G. Levy and K.M. Giacomini. Rational Aspirin Dosage Regimens. *Clin. Pharmacol. Ther*. **23**:247-252 (1978).

(3) C. Soles, K.M. Giacomini, S.M. Roberts, and J.C. Giacomini. A Convenient Method for Repetitive Blood Sampling in the Dog. *J. Pharmacol. Meth*. **1**:259-261 (1978).

(4) T.P. Gibson, K.M. Giacomini, W.A. Briggs, W. Whitman, and G. Levy. Propoxyphene and Norpropoxyphene Plasma Concentrations in The Anephric Patient. *Clin. Pharmacol. Ther*. **27**:665-670 (1980).

(5) K.M. Giacomini, T.P. Gibson, and G. Levy. Effects of Hemodialysis on Propoxyphene and Norpropoxyphene Concentrations in Blood of Anephric Patients. *Clin. Pharmacol. Ther*. **27**:508-514 (1980).

(6) K.M. Giacomini, S.M. Nakeeb, and G. Levy. Pharmacokinetic Studies on Propoxyphene I: Effect of Portacaval Anastamosis on Systemic Availability in Dogs. *J. Pharm. Sci*. **69**:786-788 (1980).

(7) K.M. Giacomini, J.C. Giacomini, T.P. Gibson, and G. Levy. Propoxyphene and Norpropoxyphene Plasma Concentrations After Oral Propoxyphene in Cirrhotic Patients With and Without Surgically Constructed Portacaval Shunt. *Clin. Pharmacol. Ther*. **28**:417-424 (1980).

(8) K.M. Giacomini, J.C. Giacomini, W. Nelson, T. Burke, S.E. Swezey, D.C. Harrison, and T.F. Blaschke. The Stereoselective Disposition of Disopyramide in the Dog. *J. Cardiovasc. Pharmacol*. **2**:825-832 (1980).

(9) K.M. Giacomini, S.E. Swezey, J.C. Giacomini, and T.F. Blaschke. Administration of Heparin Causes *In Vitro* Release of Non-Esterified Fatty Acids in Human Plasma. *Life Sci*. **27**:771-780 (1980).

(10) K.M. Giacomini, B.M. Cox, and T.F. Blaschke. Comparative Anticholinergic Effects of R- and S-Disopyramide in Longitudinal Muscle Strips from Guinea Pig Ileum. *Life Sci*. **27**:1191-1197 (1980).

(11) K.M. Giacomini, J.C. Giacomini, and T.F. Blaschke. Absence of Effect of Heparin Administration on the Binding of Prazosin and Phenytoin to Plasma Proteins. *Biochem. Pharmacol*. **29**:3337-3340 (1980).

(12) K.M. Giacomini, S.M. Roberts, and G. Levy. Evaluation of Methods for Producing Renal Dysfunction in Rats. *J. Pharm. Sci*. **70**:117-121 (1981).

(13) W.L. Nelson, C.J. Sneed, K.M. Giacomini, J.C. Giacomini, T.F. Blaschke, J. Stauss, and B.M. Cox. Synthesis and Anticholinergic Properties of the Enantiomers of 4-(Isopropyl-amino)-2-(2-Pyridyl)-2-Phenylbutyramide, the Mono-N-dealkylated Metabolite of Disopyramide. *J. Med. Chem*. **24**:614-617 (1981).

(14) K.M. Giacomini, S.E. Swezey, K. Turner-Tamiyasu, and T.F. Blaschke. The Effect of Saturable Binding to Plasma Proteins on the Pharmacokinetic Properties of Disopyramide. *J. Pharmacokin. Biopharm*. **10**:1-14 (1982).

(15) G.A. Smith, K.M. Giacomini, P. Schulz, and T.F. Blaschke. High Pressure Liquid Chromatographic Determination of Amitriptyline and Its Major Metabolites. *J. Pharm. Sci*. **71**:581-583 (1982).

(16) S.E. Swezey, K.M. Giacomini, A. Abang, C. Brass, D.A. Stevens, and T.F. Blaschke. Measurement of Ketoconozole: A New Antifungal Agent by High-Performance Liquid Chromatography. *J. Chromatog*. **227**:510-515 (1982).

(17) C. Pollick, K.M. Giacomini, K. Turner-Tamiyasu, V. Hufnagel, T.F. Blaschke, and R.L. Popp. The Cardiac Effects of d- and l- Disopyramide in Normal Subjects. A Non-Invasive Study. *Circulation* **66**:447-453 (1982).

(18) K.M. Giacomini, A. Abang, and T.F. Blaschke. Calculation of Drug Concentration in Plasma After Equilibrium Dialysis, *Br. J. Clin. Pharmacol*. **14**:752-753 (1982).

(19) P. Schulz, K. Turner-Tamiyasu, G.A. Smith, K.M. Giacomini, and T.F. Blaschke. Amitriptyline Disposition in Young and Elderly Normal Men. *Clin. Pharmacol. Ther*. **33**, 360-366 (1983).

(20) P. Schulz, A. Abang, J.C. Giacomini, T.F. Blaschke, and K.M. Giacomini. Effect of Heparin on the Red Blood Cell to Plasma Ratio of Phenytoin and Prazosin. *Ther. Drug Monit*. **5**:497-499 (1983).

(21) P. Schulz, K.M. Giacomini, S. Luttrell, K. Turner-Tamiyasu, and T.F. Blaschke. Effect of Low Doses of Heparin on the Plasma Binding of Phenytoin and Prazosin in Normal Man. *Eur. J. Clin. Pharmacol*. **25**:211-214 (1983).

(22) K.M. Giacomini and T.F. Blaschke. Effect of Concentration-Dependent Binding to Plasma Protein on the Pharmacokinetics and Pharmacodynamics of Disopyramide. *Clin. Pharmacokin*. **9**, 42-48 (1984).

(23) G.A. Smith, K.M. Giacomini, C.I. Smith, P.B. Gregory, W.H. Robinson, T.C. Merigan, and T.F. Blaschke. High-Performance Liquid Chromatographic Analysis of Hypoxanthine Arabinoside in Plasma. *J. Chromatogr*. **307**:410-415 (1984).

(24) K.M. Giacomini, F.M. Wong, and T.N. Tozer. Correction for Volume Shift During Equilibrium Dialysis by Measurement of Protein Concentration. *Pharm. Res*. **1**:179-181 (1984).

(25) K.M. Giacomini, N. Massoud, F.M. Wong, and J.C. Giacomini. Decreased Binding of Verapamil to Plasma Proteins in Patients with Liver Disease. *J. Cardiovasc. Pharmacol*. **6**:924-928 (1984).

(26) J.C. Giacomini, R.H. Zobrist, B. Dave, and K.M. Giacomini. Verapamil Interacts Stereoselectively with the Muscarinic Receptor. *Pharm. Res*. **2**:94-95 (1985).

(27) P.-H. Hsyu and K.M. Giacomini. Stereoselective Renal Clearance of Pindolol in Humans. *J. Clin. Invest*. **76**:1720-1726 (1985).

(28) J.C. Giacomini, F.M. Wong, D. Rood, and K.M. Giacomini. The Pharmacokinetics and Pharmacodynamics of *d*- and *dl*-Verapamil in Rabbits. *J. Cardiovasc. Pharmacol*. **7**:469-476 (1985).

(29) J.C. Giacomini, K.M. Giacomini, W.L. Nelson, D.C. Harrison, and T.F. Blaschke. Electrophysiology of the Enantiomers of Disopyramide in Dogs. *J. Cardiovasc. Pharmacol*. **7**, 884-890 (1985).

(30) J.C. Giacomini, W.L. Nelson, F.M. Wong, R. Boyd, R.H. Zobrist, and K.M. Giacomini. Stereoselective Interactions of 2-[(2',6'-Dimethyoxyphenoxyethyl) aminomethyl]-1,4-benzodioxane (WB-4101) with the Calcium Channel. *Biochem. Pharmacol*. **35**:716-718 (1986).

(31) P.-H. Hsyu and K.M. Giacomini. High Performance Liquid Chromatographic Determination of the Enantiomers of β-Adrenoceptor Blocking Agents in Biological Fluids I: Studies with Pindolol. *J. Pharm. Sci*. **75**, 601-605 (1986).

(32) K.M. Giacomini, C. Pollick, R. Pershe, K. Turner-Tamiyasu, and T.F. Blaschke. *In Vivo* Interaction of the Enantiomers of Disopyramide in Human Subjects. *J. Pharmacokin. Biopharm*. **14**:335-356 (1986).

(33) R.H. Zobrist, K.M. Giacomini, and J.C. Giacomini. The Interaction of Phenylalkylamine Calcium Channel Blockers with the 1,4-Dihydropyridine Binding Site. *J. Molec. Cell. Cardiol*. **18**:963-974 (1986).

(34) L.J. Theodore, W.L. Nelson, R.H. Zobrist, K.M. Giacomini, and J.C. Giacomini. Studies on Ca^{+2} Channel Antagonists. 5-[(3,4-Dimethoxyphenethyl) methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylpentyl Isothiocyanate, a Chemoaffinity Ligand Derived from Verapamil. *J. Med. Chem*. **29**:1789-1792 (1986).

(35) P.-H. Hsyu and K.M. Giacomini. The pH Gradient-dependent Transport of Organic Cations in the Renal Brush Border Membrane: Studies with Acridine Orange. *J. Biol. Chem*. **262**:3964-3968 (1987).

(36) P.-H. Hsyu and K.M. Giacomini. Essential Tyrosine Residues in Transport of Organic Cations in Renal BBMV. *Am. J. Physiol*. **252**:F1065-F1072 (1987).

(37) R. Boyd, J.C. Giacomini, F.M. Wong, W.L. Nelson, and K.M. Giacomini. Comparison of Binding Affinities and Negative Inotropic Potencies of the 1,4-Dihydropyridine Calcium Channel Blockers in Rabbit Myocardium. *J. Pharmacol. Exp. Ther*. **243**:118-125 (1987).

(38) L.G. Gisclon, F.M. Wong, and K.M. Giacomini. Cimetidine Transport in Isolated Luminal Membrane Vesicles from Rabbit Kidney. *Am. J. Physiol*. **253**:F141-F150 (1987).

(39) P.-H. Hsyu, L.G. Gisclon, and K.M. Giacomini. Interactions of Organic Anions with the Organic Cation Transporter in Renal BBMV. *Am. J. Physiol*. **254**:F56-F61 (1988).

(40) L.G. Gisclon and K.M. Giacomini. Inhibition of Cimetidine Transport by Creatinine in Luminal Membrane Vesicles Prepared from Rabbit Kidney. *Drug Metab. and Disp*. **16**:331-332 (1988).

(41) L. Valdivieso, K.M. Giacomini, W.L. Nelson, R. Pershe, and T.F. Blaschke. Stereoselective Binding of Disopyramide to Plasma Proteins. *Pharm. Res*. **5**:316-318 (1988).

(42) P.–H. Hsyu, F.M. Wong, and K.M. Giacomini. The Effect of Pindolol on the Transport of L-lysine in Renal Brush Border Membrane Vesicles. *Drug Metab. and Disp*. **16**:503-505 (1988).

(43) R.A. Boyd, J.C. Giacomini, and K.M. Giacomini. Species Differences in the Negative Inotropic Response of 1,4-Dihydropyridine Calcium Channel Blockers in Myocardium. *J. Cardiovasc. Pharmacol*. **12**:650-657 (1988).

(44) M.T. Whittico and K.M. Giacomini. Cimetidine Elimination from the Cerebrospinal Fluid of the Rat. *Pharmaceut. Res*. **5**:628-633 (1988).

(45) K.M. Giacomini, P.-H. Hsyu, and L.G. Gisclon. Renal Transport of Drugs: An Overview of Methodology with Application to Cimetidine. *Pharmaceut. Res*. **5**:465-471 (1988).

(46) R.A. Boyd, S. Chin, and K.M. Giacomini. Pharmacokinetics of the Enantiomers of Atenolol. *Clin. Pharm. Ther*. **45**:403-410 (1989).

(47) L.G. Gisclon, R.A. Boyd, and K.M. Giacomini. The Effect of Probenecid on the Renal Elimination of Cimetidine. *Clin. Pharm. Ther*. **45**:444-452 (1989).

(48) S.K. Chin, A.C. Hui, and K.M. Giacomini. High Performance Liquid Chromatographic Determination of the Enantiomers of ß-Adrenoceptor Blocking Agents in Biological Fluids. II. Studies with Atenolol. *J. Chromatograph.* **489**:438-444 (1989).

(49) R.A. Boyd, S.K. Chin, O. Don-Pedro, D. Verotta, L.B. Sheiner, R.L. Williams, and K.M. Giacomini.The Pharmacokinetics and Pharmacodynamics of Diltiazem and its Metabolites in Healthy Adults after a Single Oral Dose. *Clin. Pharm. Ther*. **46**:408-419 (1989).

(50) R. Ott, K.M. Giacomini, and A.C. Hui. Mechanisms of Interactions Between Organic Anions and the Organic Cation Transport in Renal Brush Border Membrane Vesicles. *Biochem. Pharmacol.* **40**:659-661 (1990).

(51) M. T. Whittico, G. Yuan, and K.M. Giacomini. Cimetidine Transport in Isolated Brush Border Membrane Vesicles from Bovine Choroid Plexus. *J. Pharmacol. Exp. Ther.* **255**:615-623 (1990).

(52) R.J. Ott, A.C. Hui, F.M. Wong, and K.M. Giacomini.Interactions at Quinidine and Quinine and (+)- and (-)-Pindolol with the Organic Cation/ Proton Antiporter in Renal Brush Border Membrane Vesicles. *Biochem. Pharmacol*. **41**:146-148 (1991).

(53) Y.F. Lam, R.A. Boyd, S.K. Chin, D.C. Chang, and K.M. Giacomini. Effect of Probenecid on the Pharmacokinetics and Pharmacodynamics of Procainamide. *J. Clin. Pharmacol*. **31**:429-432 (1991).

(54) G. Yuan, R. Ott, C. Salgado, and K.M. Giacomini. Transport of Organic Cations by a Renal Cell Line (OK). *J. Biol. Chem*. **266**:8978-8986 (1991).

(55) M.T. Whittico, A.C. Hui, and K.M. Giacomini. Preparation of Brush Border Membrane Vesicle from Bovine Choroid Plexus. *J. Pharmacol. Toxicol. Methods* **25**:217-227 (1991).

(56) R. Ott, A.C. Hui, G. Yuan, and K.M. Giacomini. Organic Cation Transport in Human Renal Brush Border Membrane Vesicles. *Am. J. Physiol*. **261**:F443-F451 (1991).

(57) R.J. Ott, A.C. Hui, and K.M. Giacomini. Inhibition of *N*-Linked Glycosylation Affects Organic Cation Transport across the Brush Border Membrane of Opossum Kidney Cells (OK). *J. Biol. Chem*. **267**:133-139 (1992).

(58) M. Gutierrez, C.M. Brett, R.J. Ott, A.C. Hui, and K.M. Giacomini. Nucleoside Transport in Brush Border Membrane Vesicles from Human Kidney. *Biochim. Biophys. Acta* **1105**:1-9 (1992).

(59) X. Wu, G. Yuan, C.M. Brett, A.C. Hui, and K.M. Giacomini. Sodium-dependent Nucleoside Transport in Choroid Plexus from Rabbit. *J. Biol. Chem.* **267**:8813-8818 (1992).

(60) S-W. Chang, D. Dutton, H.-L. Wang, L.S. He, R. Stearns, A. Hui, K.M. Giacomini, P. Ortiz de Montellano and N.F. Voelkel. Intact Lung Cytochrome *P*-450 Is Not Required for Hypoxic Pulmonary Vasoconstriction, *Am. J. Physiol.* **263**:L446-L453 (1992).

(61) C.M. Brett, C.B. Washington, R.J. Ott, M.M. Gutierrez and K.M. Giacomini. Interaction of Nucleoside Analogs with the Sodium-Nucleoside Transporter in Brush Border Membrane Vesicles from Human Kidney. *Pharm. Res.* **10**, 423-426 (1993).

(62) R.J. Ott, A.C. Hui, and K.M. Giacomini. Stereoselective Interactions of Organic Cations with the Organic Cation Transporter in OK Cells. *Pharm. Res.* 1**0**:1169-1173 (1993).

(63) X. Wu, A.C. Hui, and K.M. Giacomini. Formycin B. Elimination from the Cerebrospinal Fluid of the Rat. *Pharm. Res.* **10**:611-615 (1993).

(64) M.M. Gutierrez and K.M. Giacomini. Substrate Selectivity, Potential Sensitivity and Stoichiometry of Na^+-Nucleoside Transport in Brush Border Membrane Vesicles from Human Kidney. *Biochim. Biophys. Acta* **1149**:202-208 (1993).

(65) R.J. Ott, J. K. Chan, V. Ramanathan, A.C. Hui, and K.M. Giacomini Effect of Phenylisothiocyanate On Organic Cation Transport in Opossum Kidney Cells, , *J. Pharmacol. Experim. Ther.* **269**:204-208 (1994).

(66) K.M. Giacomini, D. Markovich, A. Werner, J. Biber, X. Wu and H. Murer, Expression of a Renal Na^+-Nucleoside Cotransport System (N2) in *Xenopus laevis* Oocytes, *European J. Physiol.* **427**:381-383 (1994).

(67) X. Wu and K.M. Giacomini. Expression of the Choroid Plexus Sodium-Nucleoside Cotransporter (N3) in *Xenopus laevis* Oocytes, *Biochem. Pharmacol*. **48**:432-434 (1994).

(68) S.-J. Chung, V. Ramanathan, K.M. Giacomini and C. M. Brett. Characterization of a Sodium-dependent Taurine Transporter in Rabbit Choroid Plexus, *Biochim. Biophys. Acta* **1193**:10-16 (1994).

(69) X. Wu, M. M. Gutierrez and K.M. Giacomini. Further Characterization of the Sodium-dependent Nucleoside Transporter (N3) in Choroid Plexus from Rabbit, *Biochim. Biophys. Acta* **1191**:190-196 (1994).

(70) M. M. Gutierrez and K.M. Giacomini. pression of the Choroid Plexus Sodium-Nucleoside Cotransporter in *Xenopus laevis* Oocytes, *Biochem. Pharmacol*. **48**:2251-2253 (1994).

(71) C. B. Washington, C. M. Brett , X. Wu and K.M. Giacomini. he Effect of N-ethylmaleimide on the Na^+-Nucleoside Cotransporter (N3) in Rabbit Choroid Plexus, *J. Pharmacol. Experim. Ther.* **274**:110-114 (1995).

(72) C. B. Washington and K.M. Giacomini. Mechanisms of Nucleobase Transport in Rabbit Choroid Plexus: Evidence for a Na^+-Dependent Nucleobase Transporter with Broad Substrate Selectivity, *J. Biol. Chem.* **270**:22816-22819 (1995).

(73) S-J Chung, V. K. Ramanathan, C. M. Brett and K.M. Giacomini. Saturable Disposition of Taurine in the Rat Cerebrospinal Fluid, *J. Pharmacol. Experim. Ther.* **276**, 676-682 (1995).

(74) C. B. Washington , C.M. Brett, X. Wu and K.M. Giacomini. The Effect of N-Ethylmaleimide on the Na^+-Dependent Nucleoside Transporter (N3) in Rabbit Choroid Plexus, *J. Pharmacol. Experim. Ther.* **274**. 110-114 (1995).

(75) V.K. Ramanathan, A.C. Hui, C. M. Brett and K.M. Giacomini. Primary Cell Culture of the Rabbit Choroid Plexus: An Experimental System to Investigate Membrane Transport, *Pharm. Res.* **13**, 952-956 (1996).

(76) C. B. Washington and K.M. Giacomini, Mechanisms of 5-Fluorouracil (5-FU) Transport in Isolated Rabbit Choroid Plexus Tissue Slices, *Pharm. Res.* **13**:1276-1278 (1996).

(77) S. Zevin, M. E. Schaner, N.P. Illsley and K.M. Giacomini. Guanidine Transport in a Human Choriocarcinoma Cell Line (JAR), *Pharm. Res.* **14**:401-405 (1997).

(78) V. K. Ramanathan, S.-J. Chung, K.M. Giacomini and C. M. Brett. Taurine Transport in Cultured Choroid Plexus, *Pharm. Res.* **14**:406-409 (1997).

(79) J. K. Chun, M. Piquette-Miller, L. Zhang and K.M. Giacomini. Expression of Human Polyspecific Renal Organic Cation Transport Activity in *Xenopus laevis* Oocytes. *J. Pharm. Sci.* **86**, 753-755 (1997).

(80) L. Zhang, M.J. Dresser, A.T. Gray, S.C. Yost, S. Terashita and K.M. Giacomin. Cloning and Functional Expression of a Human Liver Organic Cation Transporter. *Mol. Pharmacol.* **51**:913-921 (1997).

(81) L. Zhang, M. J. Dresser, J. K. Chun, P. C. Babbitt, and K.M. Giacomini. Cloning and Functional Characterization of a Rat Renal Organic Cation Transporter Isoform (rOCT1A). *J. Biol. Chem.* **272**:16548-16554 (1997).

(82) J. K. Chun, L. Zhang, M. Piquette-Miller, E. Lau, L.-Q. Tong, and K.M. Giacomini. Characterization of Guanidine Transport in Human Renal Brush Border Membranes. *Pharm. Res.* **14**:936-941 (1997).

(83) M. Schaner, J. Wang, S. Zevin, K. M. Gerstin, and K. M. Giacomini. Transient Expression of a Purine-Selective Nucleoside Transporter ($SPNT_{int}$) in a Human Cell Line (HeLa). *Pharm. Res.* **14**:1316-1321 (1997).

(84) V.K. Ramanathan, C. M. Brett, and K. M. Giacomini, Na^+-Dependent γ-Aminobutyric Acid (GABA) Transport in the Choroid Plexus of Rabbit. *Biochim. Biophys. Acta* **1330**:94-102 (1997).

(85) J. Wang, and K.M. Giacomini, Molecular Determinants of Substrate Selectivity in Na^+-Dependent Nucleoside Transporters. *J. Biol. Chem.* **272**:28845-28848 (1997).

(86) J. Wang, S.-F. Su, M.J. Dresser, M.E. Schaner, C.B. Washington, and K.M. Giacomini, Na^+-Dependent Purine Nucleoside Transporter from Human Kidney: Cloning and Functional Characterization. *Am. J. Physiol.* **273**:F1058-F1065 (1997).

(87) J. Wang, M.E. Schaner, S. Thomassen, S.-F. Su, M. Piquette-Miller, and K.M. Giacomini, Functional and Molecular Characteristics of Na^+-Dependent Nucleoside Transporters. *Pharm. Res.* **14**:1524-1532 (1997).

(88) K.M. Giacomini. Membrane Transporters in Drug Disposition. *J. Pharmacokin. Biopharm.* **25**:731-741 (1997)

(89) S. Terashita, M.J. Dresser, L. Zhang, A.T. Gray, S.C. Yost, and K.M. Giacomini, Molecular Cloning and Functional Expression of a Rabbit Renal Organic Cation Transporter. *Biochim. Biophys. Acta* **1369**:1-6 (1998).

(90) S. Zevin, M.E. Schaner, and K.M. Giacomini, Nicotine Transport in a Human Choriocarcinoma Cell Line (JAR). *J. Pharm. Sci.* **87**:702-706 (1998).

(91) L. Zhang, C.M. Brett, and K.M. Giacomini, Role of Organic Cation Transporters in Drug Absorption and Elimination. *Annu. Rev. Pharmacol. Toxicol.* **38**:431-60 (1998).

(92) L. Zhang, M.E. Schaner, and K.M. Giacomini, Functional Characterization of an Organic Cation Transporter (hOCT1) in a Transiently Transfected Human Cell Line (HeLa). *J. Pharmacol. Exp. Therap.* **286**:354-361 (1998).

(93) C.B. Washington, K.M. Giacomini, and C.M. Brett, Nucleoside Transport in Isolated Human and Rhesus Choroid Plexus Tissue Slices. *Pharm. Res.* **15**, 1145-1147 (1998).

(94) J. Wang and K.M. Giacomini, Characterization of a Bioengineered Chimeric Na^+-Nucleoside Transporter. *Molec. Pharmacol*. **55**:234-240 (1999).

(95) J. Wang and K.M. Giacomini, Serine 318 Is Essential for the Pyrimidine Selectivity of the N2 Na^+-Nucleoside Transporter. *J. Biol. Chem*. **274**:2298-2302 (1999).

(96) L. Zhang, W. Gorset, M.J. Dresser and K.M. Giacomini. The Interaction of n-Tetraalkylammonium Compounds with a Human Organic Cation Transporter, hOCT1. *J. Pharmacol. Exp. Ther*. **288**:1192-2298 (1999).

(97) M. Schaner, J. Wang, L. Zhang, S.-F. Su, K. Gerstin, K.M. Giacomini. Functional Characterization of a Human Purine-Selective, Na^+-Dependent Nucleoside Transporter (hSPNT1) in a Mammalian Expression System. *J. Pharmacol Exp. Ther*. **289**(3), 1487-1491 (1999).

(98) M.J. Dresser, A. Gray & K.M. Giacomini. Kinetic and Selectivity Differences Between Rodent, Rabbit and Human Organic Cation transporters (OCT1). *J. Pharmacol Exp. Ther.* **292**(3):1146-52, (2000).

(99) L. Zhang, W. Gorset, C.B. Washington, T.F. Blaschke, D.L. Kroetz, K.M. Giacomini. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. *Drug Metabolism and Disposition*. **28**(3):329-334 (2000).

(100) M.J. Dresser, K.M. Gerstin, A.T. Gray, D.D.F. Loo, K.M. Giacomini. Electrophysiological Analysis of the Substrate Selectivity of a Sodium-Coupled Nucleoside Transporter (rCNT1) Expressed in *Xenopus laevis* Oocytes. *Drug Metabolism and Disposition*. **28**(9):1135-1140 (2000).

(101) K.M. Gerstin, M.J. Dresser, J. Wang, K.M. Giacomini. Molecular Cloning of a Na^+-Dependent Nucleoside Transporter from Rabbit Intestine. *Pharm. Res.* **17**(8):906-910 (2000).

(102) G. Xiao, J. Wang, T. Tangen, K.M. Giacomini. A Novel Proton-Dependent Nucleoside Transporters, CeCNT3, from Caenorhabditis elegans. *Molec. Pharmacol.* **59**(2):339-348 (2000).

(103) L.M. Mangravite, J.H. Lipschutz, K.E. Mostov, K.M. Giacomini. Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. *Am. J Pnysiol Renal* **280**:F879-F885 (2001)

(104) M.J. Dresser, M.K. Leabman, K.M. Giacomini, Transporter Involved in the Elimination of Drugs in the Kidney: Organic Anion Transporters and Organic Cation Transporters. *Journal of Pharmaceutical Sciences*, **90**(4):397-421, 2001.

(105) B. Feng, M.J. Dresser, Y. Shu, S.J. Johns and K.M. Giacomini, Arginine 454 and Lysine 370 are Essential for the Anion Specificity of the Organic Anion Transporter, rOAT3. *Biochemistry*. **40**(8):5511-5520, 2001.

(106) C.E. Glatt, J.A. DeYoung, S. Delgado, S.K. Service, K.M. Giacomini, R.H. Edwards, N. Risch, N.B. Freimer. Screening a Large Reference Sample to Identify Very Low Frequency Sequence Variants: Comparisons between two genes. *Nature Genet.* **27:**435-438 (2001).

(107) Y. Shu, C.L. Bello, L.M. Mangravite, B. Feng, and K.M. Giacomini, Functional Characteristics and Steroid Hormone-Mediated Regulation of an Organic Cation Trasnporter in Madin-Darby Canine Kidney Cells. *J. Pharmacol Exp. Ther*., **288**(1):392-398 (2001).

(108) M.K. Leabman, C.C. Huang, M. Kawamoto, S.J. Johns, D. Stryke, T.E. Ferrin, J. DeYoung, T. Taylor, A.G. Clark, I. Herskowiz, and K.M. Giacomini, Polymorphisms in a Human Kidney Xenobiotic Transporter, OCT2, Exhibit Altered Function. Pharmacogenetics, **12**:395-405 (2002)

(109) K.M. Gerstin, M.J. Dresser, and K.M. Giacomini. Specificity of Human and Rat Orthologs of the Concentrative Nucleoside Transporters, SPNT. *Am. J. Physiol Renal* **283**:F344F348 (2002).

(110) B. Feng, Y. Shu, and K.M. Giacomini. Role of Aromatic Transmembrane Residues of the Organic Anion Transporter, rOAT3, in Substrate Recognition. *Biochemistry*, **41**: 8941-8947 (2002).

(111) M.J. Dresser, G. Xiao, M.K. Leabman, A.T. Gray, and K.M. Giacomini. Interactions of *n*-Tetraalkylammonium Compounds and Biguanides with a Human Renal Organic Cation Transporter (hOCT2). *Pharm.Res*. **19**(8):1243-46 (2002)

(112) D. Stryke, CC Huang, M. Kawamoto, SJ Johns, EJ Carlson, JA DeYoung, MK Leabman, I. Herskowitz, KM Giacomini, and TE Ferrin. Snp Analysis and Presentation in the Pharmacogenetics of Membrane Transporters Project. *Pacific Symposium on Biocomputing* 535-547 (2003).

(113) LM. Mangravite and K.M. Giacomini. Sorting of Rat SPNT in Renal Epithelium is Independent of N-Glycosylation. *Pharm. Res*. **20**:319-23 (2003)

(114) L.M. Mangravite, G. Xiao, and K.M. Giacomini. Localization of Human Equilibrative Nucleoside Transporters, hENT1 and hENT2, in Renal Epithelial Cells. *Am. J. Physiol Renal Physiol* **284**:F902-10 (2003)

(115) M.K. Leabman, C.C. Huang, J. DeYoung, E.J. Carlson, T. Taylor, M. de la Cruz, S.J. Johns, D. Stryke, M. Kawamoto, T. J. Urban, D.L. Kroetz, T.E. Ferrin, A.G. Clark, N. Risch, I. Herskowtiz, and K.M. Giacomini. Natural Variation in Human Membrane Transporter Genes Reveals Evolutionary and Functional Constraints. *Proc. Natl. Acad. Sci*. **100:**5896-901 (2003)

(116) Y. Shu, M.K. Leabman, B. Feng, L.M. Mangravite, C.C. Huang, D. Stryke, M. Kawamoto, S.J. Johns, J. De Young, E. Carlson, T.E. Ferrin, I. Herskowitz, K.M. Giacomini, and Pharmacogenetics of Membrane Transporters Investigator. Evolutionary Conservation Predicts Function of Variants of the Human Organic Cation Transporter, OCT1. *Proc. Natl. Acad. Sci*. **100**(10):5902-07 (2003).

(117) D.H. Osato, C.C. Huang, M. Kawamoto, S.J. Johns, D. Stryke, J. Wang, T.E. Ferrin, I. Herskowitz, and K.M. Giacomini. Functional Characterization in Yeast of Genetic Variants in the Human Equilibrative Nucleoside Transporter, ENT1. *Pharmacogenetics* **13**:297-301 (2003).

(118) M.K. Leabman, C. Huang, D. Stryke, S. Johns, M. Kawamoto, T. Ferrin, J. DeYoung, T. Taylor, M. Cruz, I. Herskowitz, and K.M. Giacomini. PharmGKB Update: I. Genetic Variants of the Organic Cation Transporter 2 (OCT2, SLC22A2). *Pharmacol Rev*, **55**:399 (2003).

(119) M.K. Leabman and K.M. Giacomini. Estimating the Contribution of Genes and Environment to Variation in Renal Drug Clearance. *Pharmacogenetics,* **13**:581-584 (2003).

(120) L.M. Mangravite, I. Badagnani, and K.M. Giacomini, Nucleoside Transporters in the Disposition and Targeting of Nucleoside Analogs in the Kidney. *Europeon Journal of Pharmacology,* **479**:269-281 (2003).

(121) J.H. Gray, R. Owen, K.M. Giacomini. The Concetrative Nucleoside Transporter Family, SLC28. *Eur J Physiol* **447**:728-734 (2004).

(122) J.H. Gray, L.M. Mangravite, R.P. Owen, T.J. Urban, W. Chan, ElJ. Carlson, C.C. Huang, M. Kawamoto, S.J. Johns, D. Stryke, T.E. Ferrin, and K.M. Giacomini. Functional and Genetic Diversity in the Concentrative Nucleoside Transporter, CNT1, in Human Populations. *Mol Pharmaco*l **65**:512-519 (2004).

(123) T.J. Urban, N. Risch, and K.M. Giacomini. Haplotype Structure and Ethnic-Specific Allele Frequencies at the OCTN Locus: Implications for the Genetics of Crohn Disease. *Inflammatory Bowel Diseases Journal,* **11**(1): 78-79 (2005).

(124) T.E. Ferrin, C.C. Huang, D.M. Greenblatt, D. Stryke, and K.M. Giacomini. Enhancing Data Sharing in Collaborative Research Projects with DASH. *Pacific Symposium on Biocomputing,* 260-271 (2005) Edited by R.B. Altman et al, *World Scientific Publishing*.

(125) R.P. Owen, J.H. Gray, T.R. Taylor, E.J. Carlson, C.C. Huang, M. Kawomoto, S.J. Johns, D. Stryke, T.E. Ferrin, and K.M. Giacomini. Genetic Analysis and Functional Characterization of Polymorphisms in the Human Concentrative Nucleoside Transporter, CNT2. *Pharmacogenetics and Genomic,s* **15**:83-90 (2005).

(126) I. Badagnani, W. Chan, R.A. Castro, C.M. Brett, C.C. Huang, D. Stryke, M. Kawamoto, S.J. Johns, T.E. Ferrin, E.J. Carlson, E.G. Burchard, and K.M. Giacomini. Functional Analysis of Genetic Variants in the Human Concentrative Nucleoside Transporter 3 (CNT3; SLC28A3). *J. Pharmacogenomics* **5**:157-165 (2005).

(127) T. Fujita, C. Brwon, E.J. Carlson, T. Taylor, M. Cruz, S.J. Johns, D. Stryke, M. Kawamoto, K. Fujita, R. Castro, C-W Chen, E.T. Lin, C.M. Brett, E.G. Burchard, T.E. Ferrin, C.C. Huang, M.K. Leabman, and K.M. Giacomini. Functional Analysis of Polymorphisms in the organic anion transporter, SLC22A6 (OAT1). *Pharmacogenetics and Genomics*, **15**:201-209 (2005).

(128) R. Owen, L. Lagpacan, T.R. Taylor, M. dela Cruz, C.C. Huang, M.Kawamoto, S.J. Johns, D. Stryke, T.E. Ferrin, and K.M. Giacomini. Functional Characterization and Haplotype analysis of Polymorphisms in the human equilibrative nucleoside transporter, ENT2. *Drug Metabolism and Disposition* **34**:12-15, (2006).

(129) A.R. Erdman, L.M. Mangravite, T. Urban, L. Lagpacan, R. Castro, M. dela Cruz, W. Chan, C.Ç. Huang, S.J. Johns, M. Kawamoto, D. Stryke, T.R. Tyalor, E.J. Carlson, T.E. Ferrin, C.M. Brett, E.G. Burchard, and K.M. Giacomini. The Human Organic Anion Transporter 3 (OAT3; SLC22A8): Genetic Variation and Functional Genomics. *Am J Physiol Renal Physio.*, **290**(4):F905-12, (2006).

(130) T. Urban, R. Sebro, E. Hurowitz, M. Leabman, I. Badagnani, L. Lagpacan, N. Risch and K.M. Giacomini. Functional Genomics of Membrane Transporter in Human Populations. *Genome Research* **16**: 223-230, (2006).

(131) T. Fujita, T. Urban, M. Leabman, K. Fujita, K.M. Giacomini. Transport of Drugs in the Kidney by the Human Organic Cation Transporter, OCT2 and its Genetic Variants. *J Pharmaceutical Sciences* **95**(1), 25-36, (2006).

(132) I. Badagnani, M. Sorani, R. Edwards, C. Brown, R. Castro, C. Huang, D. Stryke, M. Kawamoto, S. Johns, E. Carlson, T. Taylor, W. Chan, M. Dela Cruz, T. Ferrin, E. Burchard, I. Herskowitz, D. Kroetz and K.M. Giacomini. PharmGKB Submission Update: VI. PMT Submissions of Genetic Variations in Neurotransmitter Transporters (SLC6, SLC17, and SLC18) to the PharmGKB Network. *Pharmacological Reviews* **58**: 5-6, (2006).

(133) Y. Shu, T. Urban, M. Leabman, T. Fujita, A. Erdman, L. Lagpacan, C. Brown, R. Castro, C. Huang, D. Stryke, M. Kawamoto, S. Johns, T. Taylor, W. Chan, M. Dela Cruz, E, Carlson, T. Ferrin, C. Brett, E. Burchard, I. Herskowitz, D. Kroetz, and K.M. Giacomini. PharmGKB Submission Update: V. PMT Submissions of Genetic Variation in SLC22 Family Transporter. *Pharmacological Reviews* **58**:3-4, (2006).

(134) I. Badagnani, R. Castro, T.R. Taylor, C.M. Brett, C.C. Huang, D. Stryke, M. Kawamoto, S.J. Johns, T.E. Ferrin, E.J. Carlson, E. Burchard, and K.M. Giacomini. Interaction of Methotrexate with Orgnic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants. *J Pharm and Exp therapeutics* **318**: 521-29, Aug (2006).

(135) S. Zhang, K.S. Lovejoy, J.E. Shima, L. Lagpacan, Y. Shu, A. Lapuk, Y Chen, T Komori, J.W. Gray, X. Chen, S.J. Lippard, and K.M. Giacomini. Organic Cation Transporters are Determinants of Oxaliplatin Cytotoxicity. *Cancer Res*. **66**(17):8847-57 (2006).

(136) T. Urban, R. Gallagher, C. Brown, R. Castro, L. Lagpacan, C.Brett, T. Taylor, E.J. Carlson, E. Burchard, S. Packman, and K.M. Giacomini. Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5). *Mol Pharmacol*. PMTID: 16931768 (2006). (Figure appears on Cover).

(137) R. Owen, I. Badagnani, and K.M. Giacomini. Molecular Determinants of Specificity for Synthetic Nucleoside Analogs in the Concentrative Nucleoside Transporter, CNT2. *J Biol Chem*. **281**(36):266875-82 (2006).

(138) D.M. Roden, R.B. Altman, N.L. Benowitz, D.A. Flockhart, K.M. Giacomini, J.A. Johnson, R.M. Krauss, H.L. McLeod, M. J. Ratain, M.V. Relling, H.Z. Ring, A.R. Shuldiner, R.M. Weinshilboum, S.T. Weiss. Pharmacogenomics: Challenges and Opportunities. *Ann Intern Med*. Review **145**:749-757 (2006).

(139) K.M.Giacomini, C. Brett, R.B. Altman, N.L. Benowitz, M.E. Dolan, D.A. Flockhart, J.A. Johnson, D.F. Hayes, T. Klein, R.M. Kruass, D. Kroetz, H.L. McLeod, A.T. Nguyen, M.J. Ratain, M.V. Relling, V. Reus, D.M. Roden, C. Schaefer,, A.R. Shuldiner, T. Skaar, K. Tantisira, R.F. Tyndale, L. Wang, R.M. Weinshilboum, S.T. Weiss, I. Zineh; Pharmacogenetics Research Network. The Pharmacogenetics Research Network: from SNP Discovery to Clinical Drug Response. *Clin Pharmacol Ther.* Mar; **81**(3):328-45 (2007).

(140) K.M. Giacomini, R.M. Kruass, D.M. Roden, M. Eichelbaum, M.R. Hayden, Y. Nakamura. When Good Drugs Go Bad. *Nature*. Apr 26; **446**(7139):975-7 (2007).

(141) Y. Shu, S.A. Sheardown, C. Brown, R. Owen, S. Zhang, R. Castro, A. Ianculescu, L. Yue, J.C. Lo, E.G. Burchard, C.M. Brett, and K.M. Giacomini. Effect of Genetic Variation in the Organic Cation Transporter 1 (OCT1) on Metformin Action. *J Clin Invest*. May 1; **117**(5): 1422-1431 (2007).

(142) Y. Chen, S. Zhang, M. Sorani, and K.M. Giacomini. Transport of Paraquat by Human Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Family. *J Pharmacol Exp Ther*. Aug; **322**(2): 695-700 (2007).

(143) T.J. Urban, L.L. Lagpacan, C. Brown, R.A. Castro, T.R. Taylor, C.C. Huang, D. Stryke, S.J. Johns, M. Kawamoto, E.J. Carlson, T.E. Ferrin, E.G. Burchard, and K. M. Giacomini. Functional Effects of Protein Sequence Polymorphisms in the Organic Cation/Ergothioneine Transporter OCTN1 (SLC22A4). *Pharmcogenet Genomics*. Sep; **17**(9):773-82 (2007).

(144) R.A. Wilke, D.W. Lin, D.M. Roden, P.B. Watkins, D. Flockhart, I. Zineh, K.M. Giacomini, R.M. Krauss. Identifying Genetic Risk Factors for Serious Adverse Drug Reactions; Current Progress and Challenges. *Nat Rev Drug Discov.* Nov; **6**(11): 904-16 (2007).

(145) C.D. Cropp, T. Komori, J.E. Shima, T.J. Urban, S.W. Yee, S. More, and K.M. Giacomini. Organic Anion Transporter 2 (SLC22A7) is a Facilitative Transporter of $_c$GMP. *Mol Pharmcol.* Apr; **73**(4):1151-8 (2008).

(146) N. Huang, V. Agrawal, K.M. Giacomini, and W.L. Miller. Genetics of P450 Oxidoreductase: Sequence Variation in 842 Individuals of Four Ethnicities and Activities of 15 Missense Mutations. *Proc Natl Acad Sc*i Feb. 5; **105**(5):1733-8 (2008).

(147) N Abla, L.W. Chinn, T. Nakamura, C.C. Huang, S.J. Johns, M. Kawamoto, D. Stryke, T.R. Taylor, T.E. Ferrin, K.M. Giacomini, and D.L. Kroetz. The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of Highly Polymorphic Gene. *J Pharmacol Exp Ther.* Jun; **325**(3): 859-868 (2008).

(148) M.D. Sorani, D. Morabito, G. Rosenthal, K.M. Giacomini, and G.T. Manley. Characterizing the Dose-Response Relationship between Mannitol and Intracranial Pressure in Traumatic Brain Injury Patients Using a High-Frequency Physiological Data Collection System. *J. Neurotrauma.* Apr; **25**(4): 91-8 (2008).

(149) M.D. Sorani, G.T. Manley, and K.M. Giacomini. Genetic Variation in Human Aquaporins and Effects on Phenotypes of Water Homeostasis. *Hum Mutat* May; **29**(9): 1108-1117 (2008).

(150) M.D. Sorani, Z. Zador, E. Hurowitz, D. Yan, K.M. Giacomini, G.T. Manley. Novel Variants in Human Aquaporin-4 Reduce Cellular Water Permeability. *Hum Mol Genet*. Aug; **17**(15): 2379-89 (2008).

(151) K.S. Lovejoy, R.C. Todd, S. Zhang, M.S. McCormick, J.A.D'Aquino, J.T. Reardon, A. Sancar, K.M. Giacomini, and S.J. Lippard. cis-Diammine (pyridine) Chloroplatinum (II), a Monofunctional Paltinum (II) Antitumor Agent: Uptake, Structure, Function, and Prospects. *Proc Natl Acad Sci* Jul 1; **105**(26):8902-7 (2008).

(152) S.T. Weiss, H.L. McLeod, D.A. Flockhart, M.E. Dolan, N.L. Benowitz, J.A. Johnson, M.J. Ratain, and K.M. Giacomini. Creating and Evaluating Genetic Tests Predictive of Drug Response. Nat *Rev Drug Discov* Jul; **7**(7):568-74 (2008).

(153) Urban,T.J., C. Brown, R.A. Castro, N. Shah, R. Mercer, Y. Huang, C.M. Brett, E.G. Burchard and K.M. Giacomini. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. *Clin.Pharmacol.Ther.* **83**(3): 416-421 (2008).

(154) M. Li, F.A. Hays, Z. Roe-Zurz, L. Vuong, L. Kelly, C.M. Ho, R.M. Robbins, U. Pieper, J.D. O'Connell 3rd, L.J. Miercke, K.M. Giacomini, A. Sali, R.M. Stroud. Selecting Optimum Eukaryotic Integral Membrane Proteins for Structure Determination by Rapid Expression and Solubilization Screening. *J Mol Biol* Jan 23; **385**(3):820-30 (2009).

(155) S.W. Yee, J.E. Shima, S. Hesselson, L. Nguyen, S. De Val, R.J. Lafond, M. Kawamoto, S.J. Johns, D. Stryke, P.Y. Kwok, T.E. Ferrin, B.L. Black, D. Gurwitz, N. Ahituv, K.M. Giacomini. Identification and Characterization of Proximal Promoter Polymorphisms in the Human Concentrative Nucleoside Transporter 2 (SLC28A2). *J Pharmacol Exp Ther* Mar; **328**(3):699-707 (2009).

(156) W.L. Miller, N. Huang, V. Agrawal, K.M. Giacomini. Genetic Variation in Human P450 Oxidoreductase. *Mol Cell Endocrinol* Mar 5; **300**(1-2):180-4 (2009).

(157) A.G. Ianculescu, K.M. Giacomini, T.S. Scanlan. Identification and Characterization of 3-Iodothyronamine Intracellular Transport. *Endocrinology* Apr; **150**(4):1991-9 (2009).

(158) H. Tahara, S.W. Yee, T.J. Urban, S. Hesselson, R.A. Castro, M. Kawamoto, D. Stryke, S.J. Johns, T.E. Ferrin, P.Y. Kwok, K.M. Giacomini. Functional Genetic Variation in the Basal Promoter of the Organic Cation/ Carnitine Transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). *J Pharmacol Exp Ther*. Apr; **329**(1):262-71 (2009).

(159) Y. Chen, K. Teranishi, S. Li, S.W. Yee, S. Hesselson, D. Stryke, S.J. Johns, T.E. Ferrin, P. Kwok, K.M. Giacomini. Genetic Variants in Multidrug and Toxic Compund Extrusion-1, hMATE1, Alter Transport Function. *Pharmacogenomics J.* Apr; **9**(2):127-36 (2009).

(160) Y. Chen, S. Li, C. Brown, S. Cheatham, R.A. Castro, M.K. Leabman, T.J. Urban, L. Chen, S.W. Yee, J.H. Choi, Y. Huang, C.M. Brett, E.G. Burchard, K.M. Giacomini. Effect of Genetic Variation in the Organic Cation Transporter 2 on the renal elimination of metformin. *Pharmacogenetics and Genomics* Jul; **19**(7):497-504 (2009).

(161) McBride B.F., T. Yang, K. Liu, T.J. Urban, K.M. Giacomini, R.B. Kim, D.M. Roden. The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel. *J. Cardiovascular Pharmacology* Jul; **54**(1):63-71 (2009).

(162) Kelly, L., U. Pieper, N. Eswar, F.A. Hays, M. Li, Z. Roe-Zurz, D.L. Kroetz, K.M. Giacomini, R.M. Stroud, A. Sali. A survey of integral α-helical membrane proteins. *J. Structural and Fuctional Genomics* Dec; **10**(4): 269-280 (2009).

(163) S. E. Hesselson, P. Matsson, J.E. Shima, H. Fukushima, S.W. Yee, Y. Kobayashi, J.M. Gow, C. Ha, B. Ma, A. Poon, S.J. Johns, D. Stryke, R.A. Castro, H. Tahara, J.H. Choi, L.G. Chen, N. Picard, E. Sjodin, M.J.E. Roelofs, T.E. Ferrin, R. Myers, D.L. Kroetz, P.Y. Kwok, K.M. Giacomini. Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation**.** PLoS ONE **4**(9): e6942. doi:10.1371/journal.pone.0006942 (2009).

(164) Choi, JH, S.W. Yee, M.J. Kim, L. Nguyen, J.H. Lee, J.O. Kang, S. Hesselson, R.A. Castro, D. Stryke, S.J. Johns, P.Y. Kwok, T.E. Ferrin, M.G. Lee, B.L. Black, N. Ahituv, K.M. Giacomini. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. *Pharmacogenetics and Genomics* Oct; **19**(10): 770-780 (2009).

(165) Trevin, L.R., N. Shimasaki, W.J. Yang, J.C. Panetta, (165), C. Cheng, D.Q. Pei, D. Chan, A. Sparreboom, K.M. Giacomini, C.H. Pui, W.E. Evans, M.V. Relling. Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects**.** *J Clin Onc* Dec; **27**(35): 5972-5978 (2009).

(166) Cropp,C.D., S.W. Yee and K.M. Giacomini. Genetic Variation in Drug Transporters in Ethnic Populations (vol 84, pg, 412, 2008). *Clinical Pharmacology & Therapeutics* **85**(1): 108-109 (2009).

(167) Kroetz,D.L., N. Ahituv, E.G. Burchard, S. Guo, A. Sali and K.M. Giacomini. The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. *Pharmacogenomics* **10**(10): 1569-1576 (2009).

(168) Chen,L., M. Takizawa, E. Chen, A. Schlessinger, J.H. Choi, J. Segenthelar, A. Sali, M. Kubo, S. Nakamura, Y. Iwamoto, N. Iwasaki and K.M. Giacomini. Genetic Polymorphisms in the Organic Cation Transporter 1, OCT1, in Chinese and Japanese Populations, Exhibit Altered Function. *J.Pharmacol.Exp.Ther.* (2010).

(169) Shima,J.E., T. Komori, T.R. Taylor, D. Stryke, M. Kawamoto, S.J. Johns, E.J. Carlson, T.E. Ferrin and K.M. Giacomini. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. *Am.J.Physiol.Renal Physiol.* (2010).

(170) Picard,N., L. Levoir, F. Lamoureux, S.W. Yee, K.M. Giacomini and P. Marquet. Interaction of everolimus and sirolimus with the hepatic and intestinal Organic Anion Transporting Polypeptides (OATPs). *Fundam.Clin.Pharmacol.* **24**457 (2010).

(171) Huang,S.M., L. Zhang and K.M. Giacomini. The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA. *Clinical Pharmacology & Therapeutics* **87**(1): 32-36 (2010).

(172) More,S.S., S. Li, S.W. Yee, L. Chen, Z. Xu, D.M. Jablons and K.M. Giacomini. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. *Mol.Cancer.Ther.* **9**(4): 1058-1069 (2010).

(173) Kroetz,D.L., S.W. Yee and K.M. Giacomini. The Pharmacogenomics of Membrane Transporters Project: Research at the Interface of Genomics and Transporter Pharmacology. *Clinical Pharmacology & Therapeutics* **87**(1): 109-116 (2010).

(174) Yee,S.W., L.G. Chen and K.M. Giacomini. Pharmacogenomics of membrane transporters: past, present and future. *Pharmacogenomics* **11**(4): 475-479 (2010).

(175) Picard,N., S.W. Yee, J.B. Woillard, Y. Lebranchu, Y. Le Meur, K.M. Giacomini and P. Marquet. The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics. *Clinical Pharmacology & Therapeutics* **87**(1): 100-108 (2010).

(176) More,S.S., O. Akil, A.G. Ianculescu, E.G. Geier, L.R. Lustig and K.M. Giacomini. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. *J.Neurosci.* **30**(28): 9500-9509 (2010).

(177) Ianculescu,A.G., E.C. Friesema, T.J. Visser, K.M. Giacomini and T.S. Scanlan. Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. *Mol.Biosyst* **6**(8): 1403-1410 (2010).

(178) Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu XY, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, International Transporter. Membrane transporters in drug development. *Nature Reviews Drug Discovery.* 2010; 9(3): 215-236.

(179) Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, Apeltsin L, Stroud RM, Ferrin TE, Giacomini KM, Sali A. Comparison of human solute carriers. *Protein Science.* 2010; 19(3): 412-428.

NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:

Articles and Chapters in Books

(1) G. Levy and K.M. Giacomini. First-pass Effects in Health and Disease: Pharmacokinetic Studies on Propoxyphene. Proc. Int. Conf. Drug Absorp., Chapter 12 in *Drug Absorption* ADIS Press, pp. 115-122 (1980).

(2) T.F. Blaschke and K.M. Giacomini, Pharmacodynamic Consequences of Enantioselective Drug Disposition. In *Pharmacology*. Edited by M.J. Rand and C. Raper. Elsevier Science Publishers B.V. (Biomedical Division, 1987).

(3) K.M. Giacomini, K. Nguyen, and J.C. Giacomini. Calcium Channel Blockers, Beta Adrenergic Blocking Agents and Organic Nitrates. In *Rational Therapeutics: A Clinical Pharmacological Guide for the Health Professional.* Edited by R.W. Williams, D.C. Brater, and J. Mordenti (Marcel Dekker, Inc., New York and Basel, 1990).

(4) R.J. Ott and K.M. Giacomini. Stereoselective Transport of Drugs Across Epithelia. in Stereochemistry, edited by I. Wainer, Marcel Dekker, (1993).

(5) M.M. Gutierrez, C.M. Brett and K.M. Giacomini, Isolated Renal Brush Border and Basolateral Membrane Vesicles and Cultured Renal Cells, Chapter 11 in Models for Assessing Drug Absorption and Metabolism, edited by R. T. Borchardt, P.L. Smith and G. Wilson, Plenum Press, New York, N.Y. 10013 (1996).

(6) C.B. Washington, K.M. Giacomini and C.M. Brett, Methods to Study Drug Transport in Isolated Choroid Plexus Tissue Slices and Cultured Cells, Chapter 14 in Models for Assessing Drug Absorption and Metabolism, edited by R. Borchardt, P.L. Smith and G. Wilson, Plenum Press, New York, N.Y. 10013 (1996).

(7) R.J. Ott and K.M. Giacomini. Stereoselective Renal Handling of Drugs, In Chiral Separations: Applications and Technology. Edited by S. Ahuja, (American Chemical Society, Washington, D.C., 1997).

(8) Molecular and Functional Characteristics of Cloned Human Organic Cation Transporters. In Membrane Transporters as Drug Targets. Edited by W. Sadée, Plenum Publishing Corporation, New York, N.Y p 441-469 (1999).

(9) Marci E. Schaner, K.M. Gerstin, J. Wang, and K.M. Giacomini. Mechanisms of Transport of Nucleoside and Nucleoside Analogues in Choroid Plexus. *Advanced Drug Delivery Reviews*. 39; 51-62 (1999).

(10) K.M. Giacomini and Y. Sugiyama. Membrane Transporters and Drug Response. Goodman & Gilman's Pharmacological Basis of Therapeutics. 11th Edition: 41-70 (2006).

(11) M. Relling and K.M. Giacomini. Pharmacogenetics. Goodman & Gilman's Pharmacological Basis of Therapeutics. 11th Edition, 93-116 (2006).

(12) K.M. Giacomini and Y. Sugiyama. Membrane Transporters and Drug Response. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th Edition: 41-70 (2010).

(13) M. Relling and K.M. Giacomini. Pharmacogenetics. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th Edition, 93-116 (2010).

1 Page has been Withheld as b4 (CCI/TS) immediately following this page